Entwicklung von innovativen therapeutischen Konzepten

Microscopic view of glioblastoma tumor cells

Helmholtz Munich, together with the University of Münster and ITM Isotope Technologies Munich SE (ITM), has reported updated preliminary results from a Phase 1 clinical trial evaluating ITM-31, a targeted radiotherapy for glioblastoma. The treatment…

Prof. Marcus Conrad has been elected a member of the German National Academy of Sciences Leopoldina. With this prestigious scientific honor, the Academy recognizes his outstanding contributions to the study of regulated cell death and its…

central cancer cell being attacked by surrounding immune cells (t-cells). Ideal for medical, scientific, oncology, and health-related content

Helmholtz Munich has licensed fusion receptor technologies to the Champalimaud Foundation, where they are being used together with newly acquired T cell receptor assets to support research into engineered T cell therapies.

Porträt Marcus Conrad_KI_Erweiterung für Typo3

Prof. Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich, has been honored with the 54th Fondation ARC Léopold Griffuel Award for Translational and Clinical Research. The award recognizes his pioneering…

Electron micrograph of apoptotic cells showing the formation of membranebound apoptotic bodies a hallmark of programmed cell death

A new review in Cell by Helmholtz Munich researchers and international collaborators reframes regulated cell death as a roadmap for the next generation of precision oncology. Publication coincides with the 25th anniversary of the seminal Hallmarks of…

Porträt Marcus Conrad
Hochformat
Background: HDC Indoor

Prof. Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich was awarded the German Cancer Award 2026 in the category “Experimental Research”, together with Prof. José Pedro Friedmann Angeli of the University of…

Helmholtz Munich and Partners Report Phase 1 Results for Targeted Glioblastoma Therapy

Marcus Conrad Elected to the Leopoldina

Helmholtz Munich Technologies and Champalimaud Foundation TCR Assets Support Cellular Immunotherapy Research

Marcus Conrad Receives Fondation ARC Léopold Griffuel Award

Mapping How Cancer Cells Die – and Survive: A 25-Year Update on a Defining Hallmark of Cancer

Marcus Conrad Receives German Cancer Award 2026